In adults with difficult-to-treat atopic dermatitis in daily practice, dupilumab therapy remarkably improved work productivity and declined the associated costs.

A study (Dutch BioDay Registry) investigated the influence of dupilumab therapy on presenteeism, absenteeism, and associated costs in a large multi-centre cohort of 218 adults suffering from atopic dermatitis. 

The study recruited atopic dermatitis people who were given dupilumab therapy. With the aid of Work Productivity and Activity Impairment questionnaire, estimation of work presenteeism, absenteeism, and associated costs at the baseline and during the follow-up was done.

At week 52, a considerable drop in total work impairment and median weekly productivity losses was reported when compared to the baseline in dupilumab recipients, as shown in Table 1:

A sustained and rapid decline in work presenteeism, absenteeism, and related costs were noted in individuals having atopic dermatitis and managed with dupilumab in daily practice for about 52 weeks.